One hundred chronic alcoholics, who were hospitalized in our ward for neurological disorders directly or indirectly due to a prolonged and continual consumption of alcohol, have been treated with tiapride in doses varying from 600 up to 1200 mg/die. The drug was administered either per os or by injection. 50 of these patients were given, at the same time, graded doses of alcohol per os. The purpose of this study was to analyse the preventive and therapeutical effects of the drug both on ten "target symptoms" examined separately, and on the onset and duration of the alcohol abstinence syndrome. We have noticed that decreasing doses of alcohol, in the first days of hospitalization, were unable to reduce significantly the onset of fits of delirium tremens. Tiapride showed a reasonably good therapeutical activity on some features of the "target symptoms": it shortened the average duration of the symptoms, while it did not prove better than benzodiazepines in inhibiting the onset of the same. The drug was unable to prevent the onset of the abstinence syndrome, and, even if it had a favourable control over the symptoms, it was unable to shorten their duration. The mortality rate was similar to that of other reviews where benzodiazepines, or major drugs acting on the nervous system, were employed. The sedative action of tiapride, even at higher doses, was insignificant, and its hypnotic effect almost absent. No extrapyramidal disorders have been observed, at least up to 1000 mg/die.

Download full-text PDF

Source

Publication Analysis

Top Keywords

delirium tremens
8
doses alcohol
8
"target symptoms"
8
abstinence syndrome
8
[prevention therapy
4
therapy delirium
4
tremens tiapride]
4
tiapride] chronic
4
chronic alcoholics
4
alcoholics hospitalized
4

Similar Publications

Background: Previous studies have suggested a potential link between delirium and mitochondrial function. Consequently, this Mendelian randomisation (MR) study aimed to further investigate their causal relationship.

Methods: In this bidirectional MR study, the relationship between 73 proteins related to mitochondrial function and delirium, including delirium not induced by alcohol or other psychoactive substances (DEL) and delirium associated with alcohol withdrawal (AL-DEL).

View Article and Find Full Text PDF

Background: Pneumonia is a well-known complication in patients with severe alcohol withdrawal syndrome (SAWS). Antibiotic prophylaxis in ICU treated SAWS patients may be beneficial but data is lacking. The aims of this study were to investigate the effect of introduction of trimethoprim-sulfamethoxazole (TMP-SMX) prophylaxis, on use of broad-spectrum antibiotics and ICU length of stay (LOS) in SAWS patients with refractory delirium tremens (rDT).

View Article and Find Full Text PDF

Plasma neurofilament light chain levels are associated with delirium tremens in patients with alcohol use disorder.

Prog Neuropsychopharmacol Biol Psychiatry

November 2024

Department of Addiction Sciences, Taipei City Psychiatric Center, Taipei City Hospital, Taipei, Taiwan; Department of Psychiatry, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan; Psychiatric Research Center, Taipei Medical University Hospital, Taipei 110, Taiwan; Psychiatric Research Center, Wang-Fang Hospital, Taipei Medical University, Taipei, Taiwan. Electronic address:

Delirium tremens (DT) is the most severe and life-threatening manifestation of alcohol withdrawal. Prompt identification and treatment are crucial in the clinical management of DT, but laboratory markers in this context are still lacking. Neurofilament light chain (NfL) has been proposed as a novel blood marker of neuroaxonal pathology.

View Article and Find Full Text PDF
Article Synopsis
  • Buprenorphine is typically given sublingually for opioid withdrawal, but when that's not possible, intravenous (IV) or intramuscular (IM) methods can be effective alternatives despite limited practitioner experience in this area.
  • A case series reviewed patient charts from an urban hospital who received parenteral buprenorphine between January 2020 and December 2021, focusing on demographics, medical and substance use histories, and withdrawal outcomes.
  • Out of eight patients studied, the majority responded positively to the treatment, showing improvement in withdrawal symptoms, especially in cases with issues like delirium; no adverse effects were reported, indicating promise for this method in future applications.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!